IBA Successfully Concludes Litigation Over Competing Fiducial Marker

Indianapolis, Indiana, August 5, 2013 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the execution of a Letter of Intent to resolve litigation and claims of IBA subsidiary RadioMed Corp. against ONC Solutions, Inc. RadioMed sued ONC for misappropriation of RadioMed’s trade secrets and use of them to develop a competing linear fiducial marker called the X-Mark™.

IBA’s RadioMed affiliate invented, developed, and sells the VISICOIL™ line of fiducial markers. RadioMed alleged that ONC’s founders misappropriated technical information and the product design from RadioMed. RadioMed and ONC litigated their dispute through a jury trial and judgment. RadioMed’s claims resulted in a jury verdict for money damages, a doubling of that award for unfair or deceptive trade practices, and a court order for return to RadioMed of the patent (US 8,320,995) as well as the regulatory and technical data for the X-Mark and X-Mark Ultra.

The current agreement resolves all pending litigation between the two companies and more specifically under the Letter of Intent, ONC expresses its intent to relinquish its right to appeal and otherwise challenge the court order, immediately assigning ONC’s patent to RadioMed as well as all starting the process to transfer all X-Mark inventory to RadioMed.

“We are pleased that after 6 years, RadioMed is concluding its litigation with ONC Solutions,” says Rob Plompen, President of RadioMed’s parent entity, IBA Dosimetry. “We look forward to serving both X-Mark and VISICOIL customers in the future, ensuring RadioMed’s industry leading and patented fiducial markers are available to improve patient treatment with radiation therapy.”

As a result of this agreement, all future inquiries regarding both the X-Mark and RadioMed’s VISICOIL line of fiducial markers should be made to RadioMed. Information can be requested by contacting RadioMed at 1-866-429-0922 or visiting 2013 AAPM Annual Meeting Booth Number 1035.

About IBA
IBA (Ion Beam Applications S.A.), is the global high-tech leader in next generation radiation therapy and diagnostics of cancer. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab®
radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against

**About VISICOIL™**

VISICOIL is manufactured by RadioMed Corporation which was founded in 1997 as a private corporation and became part of IBA in 2003. VISICOIL is a patented (US Patent 8,027,712) helically wound gold coil available in various diameters and lengths to aid in the treatment of a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast, and various other organs.

The clinical success of focused, dose-delivery procedures such as image guided radiation therapy (IGRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. VISICOIL’s flexible coiled markers allow for accurate tumor localization, using a variety of visualization techniques. VISICOIL is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future therapeutic procedures, per US FDA cleared 510(K). Guided by VISICOIL, over 50,000 cancer patients worldwide have been treated with radiation therapy more safely and more accurately. VISICOIL is manufactured in various diameters and lengths by RadioMed Corporation, an IBA company. For more information about VISICOIL, please visit [www.VISICOIL.com](http://www.VISICOIL.com).

**Media Contact:**

Mike Meyer  
President  
IBA Dosimetry Americas  
3150 Stage Post Drive, Suite 110  
Bartlett, TN 38133  
Tel: (901) 386-2242  
Mike.Meyer@iba-group.com  
http://www.iba-dosimetry.com

Press release |**August 5, 2013**

###